Search research articles
Contact Us
Filters
Showing results (111-120 of 143) with videos related to
Page
of 15
Sort By:
Ebiomedicine
|
October 12, 2024
Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a two-year follow-up of the prospective clinical trial COVAXID
Puran Chen, Peter Bergman, Ola Blennow, et al.
Science Immunology
|
September 29, 2020
MAIT cell activation and dynamics associated with COVID-19 disease severity
Tiphaine Parrot, Jean-Baptiste Gorin, Andrea Ponzetta, et al.
BMC Infectious Diseases
|
January 16, 2026
Prevalence of chronic viral hepatitis B, D among Mongol migrants in Sweden compared to a sex- and age-matched native Mongol cohort
Delgersaikhan Zulkhuu, Habiba Kamal, Sanjaasuren Enkhtaivan, et al.
Clinical & Translational Immunology
|
July 14, 2021
SARS-CoV-2-specific humoral and cellular immunity persists through 9 months irrespective of COVID-19 severity at hospitalisation
John Tyler Sandberg, Renata Varnaitė, Wanda Christ, et al.
The New England Journal of Medicine
|
June 22, 2023
A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D
Heiner Wedemeyer, Soo Aleman, Maurizia Rossana Brunetto, et al.
Journal of Hepatology
|
April 12, 2026
144 Weeks of bulevirtide monotherapy for chronic hepatitis D: Final and posttreatment results from a Phase 3 randomized trial
Heiner Wedemeyer, Soo Aleman, Antje Blank, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
January 12, 2024
Distinct roles of vaccine-induced SARS-CoV-2-specific neutralizing antibodies and T cells in protection and disease
Jingyi Yan, Chandrashekar Ravenna Bangalore, Negin Nikouyan, et al.
Cell Host & Microbe
|
January 11, 2024
Memory T cells effectively recognize the SARS-CoV-2 hypermutated BA.2.86 variant
Thomas R Müller, Yu Gao, Jinghua Wu, et al.
Alimentary Pharmacology & Therapeutics
|
July 6, 2024
Clinical trial: An open-label, randomised trial of different re-start strategies after treatment withdrawal in HBeAg negative chronic hepatitis B
Asgeir Johannessen, Dag Henrik Reikvam, Soo Aleman, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
December 20, 2023
Dynamic MAIT Cell Recovery after Severe COVID-19 Is Transient with Signs of Heterogeneous Functional Anomalies
Tobias Kammann, Jean-Baptiste Gorin, Tiphaine Parrot, et al.
Page
of 15
Search research articles
Search
Showing results (111-120 of 143) with videos related to
Sort By:
Page
of 15
Ebiomedicine
|
October 12, 2024
Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a two-year follow-up of the prospective clinical trial COVAXID
Puran Chen, Peter Bergman, Ola Blennow, et al.
Science Immunology
|
September 29, 2020
MAIT cell activation and dynamics associated with COVID-19 disease severity
Tiphaine Parrot, Jean-Baptiste Gorin, Andrea Ponzetta, et al.
BMC Infectious Diseases
|
January 16, 2026
Prevalence of chronic viral hepatitis B, D among Mongol migrants in Sweden compared to a sex- and age-matched native Mongol cohort
Delgersaikhan Zulkhuu, Habiba Kamal, Sanjaasuren Enkhtaivan, et al.
Clinical & Translational Immunology
|
July 14, 2021
SARS-CoV-2-specific humoral and cellular immunity persists through 9 months irrespective of COVID-19 severity at hospitalisation
John Tyler Sandberg, Renata Varnaitė, Wanda Christ, et al.
The New England Journal of Medicine
|
June 22, 2023
A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D
Heiner Wedemeyer, Soo Aleman, Maurizia Rossana Brunetto, et al.
Journal of Hepatology
|
April 12, 2026
144 Weeks of bulevirtide monotherapy for chronic hepatitis D: Final and posttreatment results from a Phase 3 randomized trial
Heiner Wedemeyer, Soo Aleman, Antje Blank, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
January 12, 2024
Distinct roles of vaccine-induced SARS-CoV-2-specific neutralizing antibodies and T cells in protection and disease
Jingyi Yan, Chandrashekar Ravenna Bangalore, Negin Nikouyan, et al.
Cell Host & Microbe
|
January 11, 2024
Memory T cells effectively recognize the SARS-CoV-2 hypermutated BA.2.86 variant
Thomas R Müller, Yu Gao, Jinghua Wu, et al.
Alimentary Pharmacology & Therapeutics
|
July 6, 2024
Clinical trial: An open-label, randomised trial of different re-start strategies after treatment withdrawal in HBeAg negative chronic hepatitis B
Asgeir Johannessen, Dag Henrik Reikvam, Soo Aleman, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
December 20, 2023
Dynamic MAIT Cell Recovery after Severe COVID-19 Is Transient with Signs of Heterogeneous Functional Anomalies
Tobias Kammann, Jean-Baptiste Gorin, Tiphaine Parrot, et al.
Page
of 15